Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone

Gunhild Keller, Andrew V Schally, Kate Groot, Gabor L. Toller, Alexandre Havt, Frank Köster, Patricia Armatis, Gabor Halmos, Marta Zarandi, Jozsef L. Varga, Jörg B. Engel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Antagonists of growth hormone-releasing hormone (GHRH) were shown to inhibit the growth of various cancers. We investigated the antitumor activity and the mechanism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL). Nude mice bearing xenografts of RL and HT human NHL were treated with GHRH antagonists MZ-5-156 and MZ-J-7-138 at a dose of 40 μg twice daily. The concentrations of serum IGF-1 and GHRH, bFGF, and VEGF in tumor tissue were measured by radioimmunoassays. Expression of GHRH and splice variant 1 of the GHRH receptor in both cell lines was examined by RT-PCR. The effects of MZ-5-156, MZ-J-7-138 and GHRH on cell proliferation were evaluated in vitro. Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. High-affinity binding sites for GHRH and mRNA for GHRH and splice variant-1 of the GHRH receptors were found on RL and HT tumors. RL and HT cells contained GHRH peptide, and their growth in vitro was significantly inhibited by both antagonists. IGF-I levels in serum of mice were significantly decreased by antagonist MZ-5-156. Therapy with GHRH antagonists also significantly reduced tumoral bFGF, whereas VEGF levels were not suppressed. Our findings suggest that GHRH antagonists inhibit the growth of RL and HT lymphomas by direct effects mediated by tumoral receptors for GHRH. GHRH antagonists could offer a new therapeutic modality for the management of advanced NHL.

Original languageEnglish
Pages (from-to)10628-10633
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number30
DOIs
StatePublished - Jul 26 2005
Externally publishedYes

Fingerprint

Growth Hormone-Releasing Hormone
Non-Hodgkin's Lymphoma
Hormone Antagonists
Growth
Insulin-Like Growth Factor I
Vascular Endothelial Growth Factor A
Neoplasms
Serum
Heterografts
Nude Mice
Radioimmunoassay
Lymphoma

Keywords

  • Fibroblast growth factor
  • GHRH-antagonist
  • Growth factor inhibitors
  • Receptor splice variant 1

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. / Keller, Gunhild; Schally, Andrew V; Groot, Kate; Toller, Gabor L.; Havt, Alexandre; Köster, Frank; Armatis, Patricia; Halmos, Gabor; Zarandi, Marta; Varga, Jozsef L.; Engel, Jörg B.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 30, 26.07.2005, p. 10628-10633.

Research output: Contribution to journalArticle

Keller, Gunhild ; Schally, Andrew V ; Groot, Kate ; Toller, Gabor L. ; Havt, Alexandre ; Köster, Frank ; Armatis, Patricia ; Halmos, Gabor ; Zarandi, Marta ; Varga, Jozsef L. ; Engel, Jörg B. / Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 30. pp. 10628-10633.
@article{98943a0233224c178547d429c779eead,
title = "Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone",
abstract = "Antagonists of growth hormone-releasing hormone (GHRH) were shown to inhibit the growth of various cancers. We investigated the antitumor activity and the mechanism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL). Nude mice bearing xenografts of RL and HT human NHL were treated with GHRH antagonists MZ-5-156 and MZ-J-7-138 at a dose of 40 μg twice daily. The concentrations of serum IGF-1 and GHRH, bFGF, and VEGF in tumor tissue were measured by radioimmunoassays. Expression of GHRH and splice variant 1 of the GHRH receptor in both cell lines was examined by RT-PCR. The effects of MZ-5-156, MZ-J-7-138 and GHRH on cell proliferation were evaluated in vitro. Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9{\%}. High-affinity binding sites for GHRH and mRNA for GHRH and splice variant-1 of the GHRH receptors were found on RL and HT tumors. RL and HT cells contained GHRH peptide, and their growth in vitro was significantly inhibited by both antagonists. IGF-I levels in serum of mice were significantly decreased by antagonist MZ-5-156. Therapy with GHRH antagonists also significantly reduced tumoral bFGF, whereas VEGF levels were not suppressed. Our findings suggest that GHRH antagonists inhibit the growth of RL and HT lymphomas by direct effects mediated by tumoral receptors for GHRH. GHRH antagonists could offer a new therapeutic modality for the management of advanced NHL.",
keywords = "Fibroblast growth factor, GHRH-antagonist, Growth factor inhibitors, Receptor splice variant 1",
author = "Gunhild Keller and Schally, {Andrew V} and Kate Groot and Toller, {Gabor L.} and Alexandre Havt and Frank K{\"o}ster and Patricia Armatis and Gabor Halmos and Marta Zarandi and Varga, {Jozsef L.} and Engel, {J{\"o}rg B.}",
year = "2005",
month = "7",
day = "26",
doi = "10.1073/pnas.0504102102",
language = "English",
volume = "102",
pages = "10628--10633",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "30",

}

TY - JOUR

T1 - Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone

AU - Keller, Gunhild

AU - Schally, Andrew V

AU - Groot, Kate

AU - Toller, Gabor L.

AU - Havt, Alexandre

AU - Köster, Frank

AU - Armatis, Patricia

AU - Halmos, Gabor

AU - Zarandi, Marta

AU - Varga, Jozsef L.

AU - Engel, Jörg B.

PY - 2005/7/26

Y1 - 2005/7/26

N2 - Antagonists of growth hormone-releasing hormone (GHRH) were shown to inhibit the growth of various cancers. We investigated the antitumor activity and the mechanism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL). Nude mice bearing xenografts of RL and HT human NHL were treated with GHRH antagonists MZ-5-156 and MZ-J-7-138 at a dose of 40 μg twice daily. The concentrations of serum IGF-1 and GHRH, bFGF, and VEGF in tumor tissue were measured by radioimmunoassays. Expression of GHRH and splice variant 1 of the GHRH receptor in both cell lines was examined by RT-PCR. The effects of MZ-5-156, MZ-J-7-138 and GHRH on cell proliferation were evaluated in vitro. Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. High-affinity binding sites for GHRH and mRNA for GHRH and splice variant-1 of the GHRH receptors were found on RL and HT tumors. RL and HT cells contained GHRH peptide, and their growth in vitro was significantly inhibited by both antagonists. IGF-I levels in serum of mice were significantly decreased by antagonist MZ-5-156. Therapy with GHRH antagonists also significantly reduced tumoral bFGF, whereas VEGF levels were not suppressed. Our findings suggest that GHRH antagonists inhibit the growth of RL and HT lymphomas by direct effects mediated by tumoral receptors for GHRH. GHRH antagonists could offer a new therapeutic modality for the management of advanced NHL.

AB - Antagonists of growth hormone-releasing hormone (GHRH) were shown to inhibit the growth of various cancers. We investigated the antitumor activity and the mechanism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL). Nude mice bearing xenografts of RL and HT human NHL were treated with GHRH antagonists MZ-5-156 and MZ-J-7-138 at a dose of 40 μg twice daily. The concentrations of serum IGF-1 and GHRH, bFGF, and VEGF in tumor tissue were measured by radioimmunoassays. Expression of GHRH and splice variant 1 of the GHRH receptor in both cell lines was examined by RT-PCR. The effects of MZ-5-156, MZ-J-7-138 and GHRH on cell proliferation were evaluated in vitro. Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. High-affinity binding sites for GHRH and mRNA for GHRH and splice variant-1 of the GHRH receptors were found on RL and HT tumors. RL and HT cells contained GHRH peptide, and their growth in vitro was significantly inhibited by both antagonists. IGF-I levels in serum of mice were significantly decreased by antagonist MZ-5-156. Therapy with GHRH antagonists also significantly reduced tumoral bFGF, whereas VEGF levels were not suppressed. Our findings suggest that GHRH antagonists inhibit the growth of RL and HT lymphomas by direct effects mediated by tumoral receptors for GHRH. GHRH antagonists could offer a new therapeutic modality for the management of advanced NHL.

KW - Fibroblast growth factor

KW - GHRH-antagonist

KW - Growth factor inhibitors

KW - Receptor splice variant 1

UR - http://www.scopus.com/inward/record.url?scp=23044447144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044447144&partnerID=8YFLogxK

U2 - 10.1073/pnas.0504102102

DO - 10.1073/pnas.0504102102

M3 - Article

C2 - 16027368

AN - SCOPUS:23044447144

VL - 102

SP - 10628

EP - 10633

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 30

ER -